We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
No events to show.
Consensus vs. actual, and revenue trend
Rating & price-target changes
Stored first · Google News · Yahoo Finance (English)
Innate Pharma (IPHA) Q1 2026 Earnings: Deep EPS Miss Weighs on Shares as Pipeline Progress Remains in Focus - Mid-Term Outlook - newsline.com
Innate Pharma (IPHA) Q1 2026 Earnings: Deep EPS Miss Weighs on Shares as Pipeline Progress Remains in Focus - Mid-Term Outlook newsline.com
Innate Pharma Stock Tumbles 16.3% as Biotech Faces Clinical Trial Headwinds - Meyka
Innate Pharma Stock Tumbles 16.3% as Biotech Faces Clinical Trial Headwinds Meyka
Innate Pharma (Nasdaq: IPHA) outlines 2026 AGM quorum and key pipeline focus - Stock Titan
Innate Pharma (Nasdaq: IPHA) outlines 2026 AGM quorum and key pipeline focus Stock Titan
Outcome of Innate Pharma’s 2026 Annual General Meeting - Yahoo Finance
Outcome of Innate Pharma’s 2026 Annual General Meeting Yahoo Finance
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 05. 13. | After market close (AMC) | — | — | — | $2.6M | — | Scheduled |
No research actions to show.
Price data
No holdings data to show.